Although the signaling and growth factors require further investigation, we surmise that P2X7 receptor directly influences the myeloma–osteoblast and myeloma–osteoclast cross talk and therefore acknowledge the potential of P2X7 receptor as a target in MBD. This evidence concerns the gene P2RX7 and Marchiafava-Bignami disease.